Glu(OMe)-Val-Asp(OMe)-t1uoromethyl-ketone (zDEVD fmk), and ischemic damage was reduced when the drug was injected up to 9 hours after reperfusion. The protection was long lasting (21 days). Hence, the period before caspase acti vation defined the therapeutic opportunity for this neuroprotec tive agent after mild ischemic brain injury. Prolonged protec tion after caspase inhibition plus the extended treatment win dow may be especially relevant to the treatment of neurodegenerative disorders. Key Words: Transient focal ce rebral ischemia-Mild ischemia-CPP32-Caspase inhibi tor-Neuroprotection. amino acid sequence homology to CED-3 (Xue et aI., 1996) . Caspase-3 is constitutively expressed in adult mouse brain (Namura et aI., 1998) as an inactive proform (32 kDa) and is activated by posttranslational cleavage into a large and a small peptide (20 and 12 kDa) plus a short N-terminal prodomain. Caspase activity requires heterodimerization of the large and the small cleavage products and presumably promotes cell death by cleav ing nuclear and cytosolic proteins. By caspase cleavage, these substrates are either (1) activated, such as protein kinase C 0, sterol regulatory element binding proteins, caspase-activated DNase, and caspases themselves, (2) inactivated, such as DNA-dependent protein kinase, (3) disassembled, such as nuclear lamins, or (4) modified with unclear functional impact, such as poly(ADP ribose)polymerase (PARP), Ul-ribonuclear protein, and huntingtin Villa et aI., 1997; Enari et aI., 1998) .
Cleavage-site directed caspase inhibitors attenuate apoptotic cell death during development (Milligan et aI., 1995) and reduce infarct volume 24 hours after middle cerebral artery (MCA) occlusion (2 hours) if adminis-tered up to 1 hour after reperfusion (Hara et a!., 1997; Ma et aI., 1998) . Cell damage and caspase activation develop so rapidly after 2 hours of occlusion that mechanisms of protection are difficult to clarify in this model . Therefore we examined the onset of caspa se-like enzyme activity and the treatment window for caspase inhibitors in a murine model of cerebral isch emia in which cell death is delayed and apoptosis un masked. In this model of focal ischemia, the pattern of cell death (affecting predominantly neurons) resembles a type of delayed cell death that is usually seen in global ischemia. Cells die slowly over days accompanied by the appearance of terminal deoxynucleotidyl transferase mediated DNA nick-end labeling (TUNEL) plus promi nent oligonucleosomal DNA fragmentation (Endres et aI., 1998) . Neuroprotection was documented even when the caspase-inhibitor N-benzyloxycarbonyl-Asp(OMe) Glu (OMe)-Val-Asp(OMe )-fluoromethy I-ketone (zDEVD-fmk) was given 6 hours after recirculation in this model and DNA laddering was reduced. Our results now show that the window for neuroprotection is depen dent on the time of caspase activation, which is 9 hours after ischemia in this model.
MATERIALS AND METHODS

Focal cerebral ischemia model
Adult SVl29 mice (male. 18 to 22 g; Taconic Farms, Ger mantown, NY, U.S.A.) were used for this model and monitored for regional cerebral blood flow, mean arterial blood pressure, heart rate, rectal temperature, and blood gases and pH as de scribed (Hara et aI., 1996) . Rectal temperature was maintained at 37°C ± 1°C and monitored carefully in anesthetized and awake animals. Filament occlusion of the left MCA was per formed as described (Hara et aI., 1996) . Thirty minutes after ischemia, animals were briefly reanesthetized with halothane, and the filament withdrawn. zDEVD-fmk (480 ng; Enzyme Systems, Livermore, CA, U.S.A.) was administered by intra cerebroventricular injection (0.9 mm lateral, 0.1 mm posterior, 3.1 mm deep from bregma). Three days after reperfusion, ani mals were killed and the brains quickly removed and frozen. Five coronal sections (12 j.Lm thick) were taken from the brain each 2 mm caudal from the frontal pole and were stained with hematoxylin and eosin. The ischemic area on each section as reflected by sharply outlined zones of pale staining was mea sured by an investigator naive to the group identity using an image-analysis system (M4, Imaging Research, St. Catherines, Ontario, Canada) and a Zeiss microscope (x25). The total le sion volume was obtained by integrating from the areas on each section.
Mice were tested for neurologic deficits 30 minutes after ischemia onset at the time of reperfusion and scored as de scribed before (Hara et aI., 1996) : 0, no observable neurologic deficits; 1, failure to extend right forepaw; 2, circling to the contralateral side; and 3, loss of walking or righting reflex. The rater was naive to the treatment groups. Only animals with a score of 2 or more were included. Animal protocols were ap proved by the Massachusetts General Hospital's Committee on Research, Subcommittee on Research Animal Care. 1998 Caspase-3-like zDEVD-afc cleavage (DEVDase activity) assay on brain tissue homogenates Fresh brain hemispheres (after frontal and occipital pole re moval) were immediately homogenized in 4 volumes of lysis buffer (HEPES 25 mmollL, pH 7.5, 4°C) containing 0.1 % Tri ton X-I00, 5 mmollL MgCI2, 2 mmollL dithiothreitol, 74 j.LmollL antipain, 0.15 j.LmollL aprotinin, 1.3 mmollL EDTA, 1 mmollL ethyleneglycol-bis-�-aminomethylether (EGT A), 15 j.LmollL pepstatin, and 20 j.LmollL leupeptin and centrifuged at 50,000g at 4°C. Supernatant (100 j.LL) was added to HEPES buffer (900 j.LL, 100 mmollL, pH 7.4) containing 2 mmollL dithiothreitol at 25°C. After addition of the fluorogenic sub strate N-benzyloxycarbonyl-Asp-Glu-Val-Asp-7 -amino-4trifluoromethyl coumarin (zDEVD-afc, 12.5 j.LmollL; Enzyme Systems, Livermore, CA, U.S.A.), which mimics the cleavage site of PARP (DEVD216-G217), fluorescent amino-4trifluoromethyl coumarin production was measured using an Hitachi F-4500 spectrofluorometer (excitation, 400 nm; emis sion, 505 nm). Increase in fluorescence was linear between 10 and 35 minutes after adding zDEVD-afc. Caspase-3-like activ ity was calculated from the slope as fluorescence units per milligram of protein per minute and converted to picomoles per milligram per minute based on an amino-4-trifluoromethyl cou marin standard curve. DEVDase activity observed in normal brains from sham-operated animals was considered as back ground and subtracted from that in ischemic brains. Activity in the contralateral hemisphere was background level, not in hibitable by zDEVD-fmk or N-benzyloxycarbonyl-Val-Ala Asp (OMe)-fluoromethylketone (zVAD-fmk; 100 j.LmollL, re spectively; Enzyme Systems) and did not change during isch emia. However, caspase-3-like activity in the ischemic hemisphere was reduced 75% by the in vitro addition of zDEVD-fmk (l00 j.LmollL; 73% by 10 j.LmollL), added 15 min utes before the fluorogenic substrate. One hundred micromolar zDEVD-fmk is 10 times the Km for caspase-3 (9.7 mmollL; Nicholson et aI., 1995) and 10 times the concentration required to completely block caspase-3-like DEVDase activity in stau rosporine-exposed HeLa cells (Namura et aI., 1998) . One hun dred micromolar or more was able in vitro to inhibit caspase-3-like activity (Enari et aI., 1996; Armstrong et aI., 1997; EI dadah et aI., 1997) . Protein concentration was determined by photometric assay (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
CM! immunoblot on brain tissue Iysates
Brain hemispheres minus frontal (2 mm) and occipital (1 mm) poles were frozen in liquid N2, crushed and lysed in 10 mmollL HEPES buffer (pH 7.6) containing 42 mmollL KCI, 5 mmollL MgCI2, 1 mmol/L phenylmethylsulfonylfluo ride, 1 mmollL EDTA, I mmollL EGTA, 1 mmollL dithio threitol, I % sodium lauryl sulfate, 1.5 j.LmollL pepstatin, 2 j.LmollL leupeptin, and 0.7 j.LmollL aprotinin, and centrifuged at 20,800g. Samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a nitro cellulose membrane. Blots were probed with two different polyclonal antibodies. Caspase-3 antiserum was raised against a IO-amino acid peptide (C12SIKNFEVKT20 in hamster) lo cated close to the N-terminus of caspase-3 prodomain (amino acids 12 through 20; Wang et aI., 1996) and therefore recog nized both caspase-3p32 and its p20 cleavage product. A rabbit poly clonal antiserum, CM I, was raised against a 13-amino acid peptide (l63CRGTELDCGIETD 175) covering the active site cysteine and extending to the C-terminus of the p20 cleavage product of human and mouse caspase-3 (Armstrong et aI., 1997; Namura et aI., 1998) . We previously reported that im-munostaining was significantly reduced by preabsorbtion with either peptide immunogen (SIKNFEVKT for caspase-3p32; CRGTELDCGIETD for CMl (Namura et aI., 1998) . Blot bands were quantified by measuring optical density (OD; Bio Rad GS-700). Differences in OD of 20-kDa and 32-kDa bands over time or between ischemic and contralateral hemispheres were always determined based on the comparison with the corresponding a-tubulin bands.
Cell counting
To quantify viable cells in the center of the striatal lesion, cells with a nonpyknotic nucleus were counted in a OA-mm 2 field in a section (20 fLm thick; stained with hematoxylin and eosin) through the anterior commissure. Cells with a rod shaped nucleus, which were assumed to be glia, were not counted.
Statistics
Caspase-like activity time course and cell counts were ana lyzed by one-way analysis of variance followed by Dunnett and Scheffe post hoc tests, respectively. Infarct volume, single caspase-like activity data points and optical densities on blots were compared with the corresponding controls by Student's t tests. A P less than 0.05 was considered significant.
RESULTS
Caspase activation after mild focal ischemia
Thirty minutes of reversible MCA occlusion caused the slow development of apoptotic cell death as evi denced by the first appearance of TUNEL-positive cells and DNA laddering at 24 hours, peaking at 72 hours (Endres et aI., 1998 Reperfusion time (h) measured in brain lysates using the fluorogenic substrate zDEVD-afc, DEVDase activity was detected initially 9 hours after 30 minutes of occlusion, increased at 12 hours, and sustained until 24 hours after reperfusion (Fig.  lA) . Using antiserum against the carboxy-terminus of the 20-kDa caspase-3 fragment (p20), we detected a faint band at 9 hours that became more intense at 12 and 24 hours (Fig. lB, middle panel) . A decrease in unprocessed immunoreactive caspase-3 ( Fig. lB, upper panel) was detected at 24 hours (see Fig. IB legend) and 30 hours (not shown).
zDEVD-fmk administration inhibits caspase activation
When zDEVD-fmk was injected intracerebroventricu larly, immediately before MCA occlusion (Fig. 2) caspase-like activity in brain homogenate was almost completely inhibited 12 or 24 hours later. Administration at 6 hours also significantly reduced DEVDase activity when measured during peak activity (12 hours) (18.4 ± 8.5 versus 1.7 ± 2.9 pmol'mg-1 'min-1 ; n = 5 to 6; P < 0.05). Reportedly, caspase-7 and caspase-l cleave zDEVD-afc (Juan et aI., 1997; Thornberry et aI., 1997) . However, caspase-7 is not expressed in mouse brain (Juan et aI., 1997) , and zDEVD-fmk treatment did not attenuate elevated interleukin-113 levels in ischemic brain as observed after caspase-l inhibition (Hara et aI., 1997) . Therefore, among the known family members expressed in brain, caspase-3 is tentatively identified as the pre- , 9, 12 , and 24 hours after reperfusion after 30 minutes of occlusion. Ten milligrams of protein was loaded per lane and the membrane was probed with 1: 1,500 dilution of either antiserum. Caspase-3 cleavage product (p20) was increased slightly at 9 hours and was clearly present at 12 to 24 hours. Caspase-3 precursor (p32) protein was decreased in left hemisphere compared with contralateral side at 24 hours (00 left, 0.22 ± 0.05 versus right, 0.33 ± 0.03; mean ± SO; n = 4; P < 0.01). This was also observed 30 hours after reperfusion (data not shown; 00 left, 0.21 ± 0.06 versus right, 0.29 ± 0.05; mean ± SO; n = 4; P < 0.05). a-Tubulin was used as a control for protein loading (lower panel). Antibodies for p20 and p32 have been characterized previously (Namura et aI., 1998) . The experiments were repeated 4 times with identical results; a representative blot is shown. Caspase-3 cleavage was not observed on the contralateral side (not shown), although a faint p20 band was sometimes found at 24 hours (not shown). dominant enzyme cleaving the fluorogenic substrate in this study, consistent with a decrease in unprocessed im munoreactive caspase-3 on immunoblots.
zDEVD-fmk protects from ischemic cell death zDEVD-fmk (480 ng) treatment significantly reduced ischemic injury when given immediately before ischemia (55%), or during reperfusion at 6 hours (57%) or 9 hours
3. Injury volume after intracerebroventricular injection of zDEVD-fmk (480 ng) before cerebral ischemia or 6 to 12 hours after reperfusion (black bars; n = 7 to 9) or in controls injected with vehicle at the same time points (dimethylsulfoxide, 0.4%; clear bars; n = 6 to 10). Mice were subjected to filament occlusion of the MCA for 30 minutes and reperfused for 72 hours. Mean ± SD; * P < 0.01, compared with the corresponding vehicle controls.
J Cereb Blood Flow Metab. Vol. 18. No. 10, 1998 (45%) (Fig, 3) . Neurologic deficits were also improved in the treated groups, suggesting that drug-induced neu ronal sparing enhanced sensory-motor performance. Protection sustained when tested at 7 days (Fig. 4A ). Even at 21 days, greater numbers of viable neurons were present in ischemic striatum (Fig. 4B ). Hence, caspase like inhibition not only postponed apoptotic cell death, but protected cells in a long-lasting way. Because zDEVD-fmk treatment did not modify regional cerebral blood flow, mean arterial blood pressure, heart rate, ar terial pH, Paco2, Pao2, or rectal temperature, we con clude that zDEVD-fmk protects ischemic tissue and pre serves neurologic function probably by direct cytopro tective mechanisms involving caspase inhibition.
DISCUSSION
The treatment window for zDEVD-fmk corresponds to the onset of caspase activation zDEVD-fmk (480 ng) protected brain when injected up to 9 hours after restoration of blood flow, but not when administered 12 hours after reperfusion (Fig. 1) . The 9-hour treatment window corresponded to the onset of both DEVDase activation and caspase-3 cleavage. Hence, zDEVD-fmk protected against the development of ischemic injury if given before enzyme activation. When injected at time points later than 9 hours, cell death became uncoupled from caspase inhibition presumably because of activation of downstream caspase processing and cleavage of multiple substrates. The long-lasting in hibition of caspase-3-like activity by zDEVD-fmk is caused by irreversible alkylation of the active site cyste ine sulfur of caspase-3 by the fluoromethylketone moiety of zDEVD-fmk (Thornberry et aI., 1994) .
How is caspase-3 activation initiated after mild brain ischemia? Current literature suggests several possible upstream events including caspase-l, caspase-8, and granzyme B . Cytochrome c release from mitochondria and the dissociation of Bcl-2 from a complex of mammalian CED-4 homologue Apaf-l ) plus caspase-3 may promote cleavage and caspase-3 processing (Chinnaiyan et a!., 1997; Hengart ner, 1997) . Cycloheximide, which can attenuate mild ischemic damage in this mouse model (Endres et aI., 1998) and in the rat (Du et a!., 1996) , may inhibit new protein synthesis, or alternatively promote bcl-2 upregu lation (Furukawa et aI., 1997) . The importance of free radicals, DNA damage, mitochondrial injury, and p53 upregulation and Fas receptor-mediated formation of death-inducing stimulus complex needs further study (MacManus and Linnik, 1997) .
The findings in this study are important for several reasons. DEVDase activity provides the first tissue marker that can be used to assess a therapeutic window for caspase-mediated neuroprotection. The treatment window in this case corresponded to the onset of caspase activation. To our knowledge, this is the first biochemi cal marker to define a treatment window for any class of therapeutic agents in stroke. Second, the therapeutic win dow for caspase inhibition after mild ischemia (30 min utes) is considerably longer than for most drugs success ful in models of focal cerebral ischemia (generally less than 2 hours after reperfusion) and protection was long lasting (21 days after treatment). Although experience in testing drugs in this model is relatively limited, the thera peutic window for MK-801, an N-methyl-o-aspartate re ceptor blocker, was not extended in this model (Endres et aI., 1998) . Because caspase activation may be relevant to slowly evolving cell death after brief cerebral ischemia or in neurodegenerative diseases such as Alzheimer's disease (Yang et aI., 1998) , Huntington's disease (Gold berg et aI., 1996) , and amyotrophic lateral sclerosis (Friedlander et aI., 1997) , our findings emphasize the importance of developing caspase inhibitors, which may be useful for treatment of neurologic diseases in addition to acute focal cerebral ischemia in man.
